Physiological measures: heart rate and core temperature · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Physiological measures: gastric tachyarrhythmia10 Assessed by: electrogastrography · patients with motion sickness
1 finding from 1 review
Adverse effects: 1. Sedation · patients with motion sickness
Antihistamines may leads to higher adverse effects: sedation Assessed by: adverse effect questionnaire… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: impaired cognition Assessed by: adverse effect questionnaire (presence or absence given numerical values) · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: impaired cognition Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: blurred vision Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Tinnitus symptom severity · adults with tinnitus
1 finding from 1 review
Serious adverse effects (bleeding or seizures) · adults with tinnitus
1 finding from 1 review
Tinnitus loudness · adults with tinnitus
1 finding from 1 review
Health‐related quality of life · adults with tinnitus
1 finding from 1 review
Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus
Ginkgo biloba showed no clear difference in other adverse effects (gastrointestinal upset, headache, allergic… compared with placebo (low certainty).
1 finding from 1 review
Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).
2 findings from 1 review
Other adverse effects · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review